Differential expression of transcriptional regulatory units in the prefrontal cortex of patients with bipolar disorder: potential role of early growth response gene 3

Translational Psychiatry

Volumn 6, Issue 5, 2016, Pages

  Pfaffenseller, B ^a,b   da Silva Magalhaes P V ^a,b   De Bastiani, M A ^b   Castro, M A A ^c   Gallitano, A L ^d   Kapczinski, F ^a,b   Klamt, F ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; EARLY GROWTH RESPONSE FACTOR 3; EGR3 PROTEIN, HUMAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; ILF2 PROTEIN, HUMAN; INTERLEUKIN ENHANCER BINDING FACTOR 2; MADD PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TSC22D4 PROTEIN, HUMAN; Y BOX BINDING PROTEIN 1; YBX1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; BIPOLAR DISORDER; CASE CONTROL STUDY; FEMALE; GENE REGULATORY NETWORK; GENETICS; HUMAN; LASER CAPTURE MICRODISSECTION; MALE; METABOLISM; MIDDLE AGED; PREFRONTAL CORTEX; YOUNG ADULT;

ADOLESCENT; ADULT; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; EARLY GROWTH RESPONSE PROTEIN 3; FEMALE; GENE REGULATORY NETWORKS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; NUCLEAR FACTOR 45 PROTEIN; PREFRONTAL CORTEX; TRANSCRIPTION FACTORS; TRANSCRIPTOME; Y-BOX-BINDING PROTEIN 1; YOUNG ADULT;

EID: 85013185307     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2016.78     Document Type: Article

References (70)

1. Kieseppa T, Partonen T, Haukka J, Kaprio J, Lönnqvist J. High concordance of bipolar I disorder in a nationwide sample of twins. Am J Psychiatry 2004; 161: 1814–1821.
2. Craddock N, Sklar P. Genetics of bipolar disorder. Lancet 2013; 381: 1654–1662.
3. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748–752.
4. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. Am J Hum Genet 2011; 88: 294–305.
5. Gershon ES, Alliey-Rodriguez N, Liu C. After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am J Psychiatry 2011; 168: 253–256.
6. Altar CA, Vawter MP, Ginsberg SD. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 2009; 34: 18–54.
7. McCullumsmith RE, Meador-Woodruff JH. Novel approaches to the study of postmortem brain in psychiatric illness: old limitations and new challenges. Biol Psychiatry 2011; 69: 127–133.
8. Seifuddin F, Pirooznia M, Judy JT, Goes FS, Potash JB, Zandi PP. Systematic review of genome-wide gene expression studies of bipolar disorder. BMC Psychiatry 2013; 13: 213.
9. Hawrylycz M, Ng L, Page D, Morris J, Lau C, Faber S et al. Multi-scale correlation structure of gene expression in the brain. Neural Netw 2011; 24: 933–942.
10. Price JL, Drevets WC. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 2012; 16: 61–71.
11. Margolin AA, Wang K, Lim WK, Kustagi M, Nemenman I, Califano A. Reverse engineering cellular networks. Nat Protoc 2006; 1: 662–671.
12. Castro MA, de Santiago I, Campbell TM, Vaughn C, Hickey TE, Ross E et al. Regulators of genetic risk of breast cancer identified by integrative network analysis. Nat Genet 2016; 48: 12–21.
13. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010; 463: 318–325.
14. Piao G, Saito S, Sun Y, Liu ZP, Wang Y, Han X et al. A computational procedure for identifying master regulator candidates: a case study on diabetes progression in Goto-Kakizaki rats. BMC Syst Biol 2012; 6(Suppl 1): S2.
15. Fletcher MN, Castro MA, Wang X, de Santiago I, O'Reilly M, Chin SF et al. Master regulators of FGFR2 signaling and breast cancer risk. Nat Commun 2013; 4: 2464.
16. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011; 478: 519–523.
17. Harris LW, Wayland M, Lan M, Ryan M, Giger T, Lockstone H et al. The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One 2008; 3: e3964.
18. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry 2006; 11: 965–978.
19. Castro MA, Wang X, Fletcher MN, Meyer KB, Markowetz F. RedeR: R/Bioconductor package for representing modular structures, nested networks and multiple levels of hierarchical associations. Genome Biol 2012; 13: R29.
20. Meyer PE, Lafitte F, Bontempi G. minet: A R/Bioconductor package for inferring large transcriptional networks using mutual information. BMC Bioinformatics 2008; 9: 461.
21. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545–15550.
22. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929–1935.
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3.
24. O'Donovan KJ, Tourtellotte WG, Millbrandt J, Baraban JM. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends Neurosci 1999; 22: 167–173.
25. Yamagata K, Kaufmann WE, Lanahan A, Papapavlou M, Barnes CA, Andreasson KI et al. Egr3/Pilot, a zinc finger transcription factor, is rapidly regulated by activity in brain neurons and colocalizes with Egr1/zif268. Learn Mem 1994; 1: 140–152.
26. Jones MW, Errington ML, French PJ, Fine A, Bliss TV, Garel S et al. A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci 2001; 4: 289–296.
27. Gallitano-Mendel A, Izumi Y, Tokuda K, Zorumski CF, Howell MP, Muglia LJ et al. The immediate early gene early growth response gene 3 mediates adaptation to stress and novelty. Neuroscience 2007; 148: 633–643.
28. Li L, Yun SH, Keblesh J, Trommer BL, Xiong H, Radulovic J et al. Egr3, a synaptic activity regulated transcription factor that is essential for learning and memory. Mol Cell Neurosci 2007; 35: 76–88.
29. Cheval H, Chagneau C, Levasseur G, Veyrac A, Faucon-Biguet N, Laroche S et al. Distinctive features of Egr transcription factor regulation and DNA binding activity in CA1 of the hippocampus in synaptic plasticity and consolidation and recon-solidation of fear memory. Hippocampus 2012; 22: 631–642.
30. Li L, Carter J, Gao X, Whitehead J, Tourtellotte WG. The neuroplasticity-associated arc gene is a direct transcriptional target of early growth response (Egr) transcription factors. Mol Cell Biol 2005; 25: 10286–10300.
31. Maple AM, Zhao X, Elizalde DI, McBride AK, Gallitano AL. Htr2a expression responds rapidly to environmental stimuli in an Egr3-dependent manner. ACS Chem Neurosci 2015; 6: 1137–1142.
32. Gallitano-Mendel A, Wozniak DF, Pehek EA, Milbrandt J. Mice lacking the immediate early gene Egr3 respond to the anti-aggressive effects of clozapine yet are relatively resistant to its sedating effects. Neuropsychopharmacology 2008; 33: 1266–1275.
33. Williams AA, Ingram WM, Levine S, Resnik J, Kamel CM, Lish JR et al. Reduced levels of serotonin 2 A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine. Neuropsychopharmacology 2012; 37: 2285–2298.
34. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG et al. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 1995; 14: 433–445.
35. Roberts DS, Hu Y, Lund IV, Brooks-Kayal AR, Russek SJ. Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. J Biol Chem 2006; 281: 29431–29435.
36. Thiel G, Schoch S, Petersohn D. Regulation of synapsin I gene expression by the zinc finger transcription factor zif268/egr-1. J Biol Chem 1994; 269: 15294–15301.
37. Petersohn D, Schoch S, Brinkmann DR, Thiel G. The human synapsin II gene promoter. Possible role for the transcription factor zif268/egr-1, polyoma enhancer activator 3, and AP2. J Biol Chem 1995; 270: 24361–24369.
38. Hippenmeyer S, Shneider NA, Birchmeier C, Burden SJ, Jessell TM, Arber S. A role for neuregulin1 signaling in muscle spindle differentiation. Neuron 2002; 36: 1035–1049.
39. Gerber DJ, Hall D, Miyakawa T, Demars S, Gogos JA, Karayiorgou M et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA 2003; 100: 8993–8998.
40. Yamada K, Gerber DJ, Iwayama Y, Ohnishi T, Ohba H, Toyota T et al. Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proc Natl Acad Sci USA 2007; 104: 2815–2820.
41. Huentelman MJ, Muppana L, Corneveaux JJ, Dinu V, Pruzin JJ, Reiman R et al. Association of SNPs in EGR3 and ARC with schizophrenia supports a biological pathway for schizophrenia risk. PLoS One 2015; 10: e0135076.
42. González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M et al. Tran-scriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 2003; 23: 8836–8843.
43. Manji HK, Quiroz JA, Payne JL, Singh J, Lopes BP, Viegas JS et al. The underlying neurobiology of bipolar disorder. World Psychiatry 2003; 2: 136–146.
44. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804–817.
45. Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR, Colpo G et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar dis-orders: a systematic review and meta-regression analysis. J Psychiatr Res 2011; 45: 995–1004.
46. Frey BN, Andreazza AC, Houenou J, Jamain S, Goldstein BI, Frye MA et al. Bio-markers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry 2013; 47: 321–332.
47. Weigelt K, Carvalho LA, Drexhage RC, Wijkhuijs A, de Wit H, van Beveren NJ et al. TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain Behav Immun 2011; 25: 1162–1169.
48. Kim JH, Roberts DS, Hu Y, Lau GC, Brooks-Kayal AR, Farb DH et al. Brain-derived neurotrophic factor uses CREB and Egr3 to regulate NMDA receptor levels in cortical neurons. J Neurochem 2012; 120: 210–219.
49. Gao X, Daugherty RL, Tourtellotte WG. Regulation of low affinity neurotrophin receptor (p75(NTR)) by early growth response (Egr) transcriptional regulators. Mol Cell Neurosci 2007; 36: 501–514.
50. Dechant G, Barde YA. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci 2002; 5: 1131–1136.
51. Farris S, Lewandowski G, Cox CD, Steward O. Selective localization of arc mRNA in dendrites involves activity-and translation-dependent mRNA degradation. J Neurosci 2014; 34: 4481–4493.
52. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 2012; 17: 142–153.
53. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014; 506: 179–184.
54. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014; 506: 185–190.
55. Guo AY, Sun J, Jia P, Zhao Z. A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst Biol 2010; 4: 10.
56. Gallitano AL, Tillman R, Dinu V, Geller B. Family-based association study of early growth response gene 3 with child bipolar I disorder. J Affect Disord 2012; 138: 387–396.
57. Mansour HA, Talkowski ME, Wood J, Chowdari KV, McClain L, Prasad K et al. Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disord 2009; 11: 701–710.
58. Byrne EM, Heath AC, Madden PA, Pergadia ML, Hickie IB, Montgomery GW et al. Testing the role of circadian genes in conferring risk for psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet 2014; 165B: 254–260.
59. Kim SH, Song JY, Joo EJ, Lee KY, Ahn YM, Kim YS. EGR3 as a potential susceptibility gene for schizophrenia in Korea. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1355–1360.
60. Zhang R, Lu S, Meng L, Min Z, Tian J, Valenzuela RK et al. Genetic evidence for the association between the early growth response 3 (EGR3) gene and schizophrenia. PLoS One 2012; 7: e30237.
61. Liu BC, Zhang J, Wang L, Li XW, Wang Y, Ji J et al. No association between EGR gene family polymorphisms and schizophrenia in the Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 506–509.
62. Kyogoku C, Yanagi M, Nishimura K, Sugiyama D, Morinobu A, Fukutake M et al. Association of calcineurin A gamma subunit (PPP3CC) and early growth response 3 (EGR3) gene polymorphisms with susceptibility to schizophrenia in a Japanese population. Psychiatry Res 2011; 185: 16–19.
63. Nishimura Y, Takizawa R, Koike S, Kinoshita A, Satomura Y, Kawasaki S et al. Association of decreased prefrontal hemodynamic response during a verbal flu-ency task with EGR3 gene polymorphism in patients with schizophrenia and in healthy individuals. Neuroimage 2014; 85(Pt 1): 527–534.
64. Shinozaki G, Potash JB. New developments in the genetics of bipolar disorder. Curr Psychiatry Rep 2014; 16: 493.
65. Kim SH, Yu HS, Park HG, Ahn YM, Kim YS, Lee YH et al. Egr1 regulates lithium-induced transcription of the Period 2 (PER2) gene. Biochim Biophys Acta 2013; 1832: 1969–1979.
66. Almutawaa W, Kang NH, Pan Y, Niles LP. Induction of neurotrophic and differentiation factors in neural stem cells by valproic acid. Basic Clin Pharmacol Toxicol 2014; 115: 216–221.
67. Cheng MC, Liao DL, Hsiung CA, Chen CY, Liao YC, Chen CH. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol 2008; 11: 207–216.
68. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphe-tamine. Proc Natl Acad Sci USA 1992; 89: 4270–4274.
69. Moratalla R, Robertson HA, Graybiel AM. Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum. J Neurosci 1992; 12: 2609–2622.
70. Beckmann AM, Wilce PA. Egr transcription factors in the nervous system. Neurochem Int 1997; 31: 477–510.